Last reviewed · How we verify
Mometasone furoate 0.1% cream
Mometasone furoate is a topical corticosteroid that suppresses local inflammatory and immune responses in the skin by binding to glucocorticoid receptors.
Mometasone furoate is a topical corticosteroid that suppresses local inflammatory and immune responses in the skin by binding to glucocorticoid receptors. Used for Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, Atopic dermatitis, Contact dermatitis.
At a glance
| Generic name | Mometasone furoate 0.1% cream |
|---|---|
| Sponsor | Montefiore Medical Center |
| Drug class | Topical corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Mometasone furoate is a medium-to-high potency glucocorticoid that reduces inflammation, itching, and skin irritation by activating intracellular glucocorticoid receptors, which then modulate the expression of pro-inflammatory cytokines and immune mediators. When applied topically as a cream, it penetrates the stratum corneum and dermis to exert localized anti-inflammatory effects while minimizing systemic absorption.
Approved indications
- Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses
- Atopic dermatitis
- Eczema
- Psoriasis
- Contact dermatitis
Common side effects
- Skin atrophy
- Striae
- Telangiectasia
- Local irritation or burning
- Folliculitis
Key clinical trials
- Safety and Efficacy of Intralesional 0.5% Triamcinolone Acetonide in 0.2% Fluconazole Solution vs 0.1% Topical Mometasone Furoate With 2% Miconazole Nitrate Cream in the Treatment of Chronic Paronychia: An Intraindividual Randomized Controlled Trial. (PHASE3)
- 0.005% Latanoprost Gel for Nonsegmental Vitiligo (PHASE2)
- Prebiotic Effects of Mulberry Fruit in Children and Adolescents With Atopic Dermatitis (NA)
- Comparison of Effectiveness and Safety of Triple Combination Cream of Fucinolone Acetonide 0.01%, Hydroquinone 4%, Tretinoin 0.05% with Mometasone Furoate 0.1%, Hydroquinone 4%, Tretinoin 0.05% in the Treatment of Melasma (NA)
- Dermatitis During Adjuvant Irradiation for BREAst Cancer: (NA)
- Elocon vs Fluticasone in Localized Psoriasis (P03197) (PHASE4)
- Topical Steroids & Bacterial Decolonization for Radiation Dermatitis (PHASE2)
- Staphylococcus Aureus and The Skin Microbiome During Flare And Resolution Of Atopic Dermatitis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mometasone furoate 0.1% cream CI brief — competitive landscape report
- Mometasone furoate 0.1% cream updates RSS · CI watch RSS
- Montefiore Medical Center portfolio CI